title: Progress in the development of Fasciola hepatica vaccine using recombinant fatty acid binding protein with the adjuvant adaptation system ADAD.
abstract: Fatty acid binding proteins (FABP) have been designed as a potential vaccine against fasciolosis. In this work, the immunoprophylaxis of the recombinant Fh15 FABP from F. hepatica (Fh15) in adjuvant/immunomodulator ADAD system was evaluated using mice and sheep challenged with F. hepatica. The ADAD system combines the Fh15 antigen with an immunomodulator (hydroalcoholic extract of Polypodium leucotomos; PAL) and/or an adjuvant (saponins of Quillaja saponaria; Qs) in a water/oil emulsion (30/70) with a non-mineral oil (Montanide). All the infected control mice died by 41-48 days post-infection. The mice vaccinated with ADAD only with PAL+Fh15 present a survival rate of 40-50% and those vaccinated with ADAD containing PAL+Qs+Fh15 had a survival rate of 50-62.5%. IgG1 antibodies were lower in surviving mice in comparison with non-surviving mice. The sheep vaccinated with ADAD PAL+Qs+Fh15 showed lower fluke recovery (43%), less hepatic lesions and higher post-infection daily weight gain than F. hepatica infected control animals. Thus, the ADAD system using recombinant fatty acid binding proteins from F. hepatica could be a good option to develop vaccines against F. hepatica.
authors.affiliation: Laboratorio de Parasitología, Facultad de Farmacia, Universidad de Salamanca, Avda. Campo Charro s/n, 37007 Salamanca, Spain.
authors.forename: J
authors.initials: J
authors.lastname: López-Abán
authors.forename: P
authors.initials: P
authors.lastname: Casanueva
authors.forename: J
authors.initials: J
authors.lastname: Nogal
authors.forename: M
authors.initials: M
authors.lastname: Arias
authors.forename: P
authors.initials: P
authors.lastname: Morrondo
authors.forename: P
authors.initials: P
authors.lastname: Diez-Baños
authors.forename: G V
authors.initials: GV
authors.lastname: Hillyer
authors.forename: A R
authors.initials: AR
authors.lastname: Martínez-Fernández
authors.forename: A
authors.initials: A
authors.lastname: Muro
mesh_terms: D000818:Animals; D002626:Chemistry, Pharmaceutical; D005210:Fasciola hepatica / Q000276:immunology; D005211:Fascioliasis / Q000517:prevention & control*; D050556:Fatty Acid-Binding Proteins / Q000276:immunology*; D005260:Female; D051379:Mice; D008807:Mice, Inbred BALB C; D011994:Recombinant Proteins / Q000276:immunology*; D012756:Sheep; D012757:Sheep Diseases / Q000469:parasitology / Q000517:prevention & control*; D013997:Time Factors; D014612:Vaccines / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology*
chemical_list: D050556:Fatty Acid-Binding Proteins; D011994:Recombinant Proteins; D014612:Vaccines